Clinical Research in Southampton
Southampton Children's Hospital

A A A Text only | Accessibility | Privacy and cookies

Home
About the Trust
Our services
Patients and visitors
Our hospitals
Education
Research
Working here
Contact us

Browse site A to Z

A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

Search results

Go To Advanced Search

Search

You could also try: determined (252), resolute (3)

Fulvestrant-Ribociclib

Description: Chemotherapy Protocol Breast Cancer Fulvestrant-Ribociclib Regimen • Breast Cancer – Fulvestrant-Ribociclib Indication • Fulvestrant and ribociclib is indicated for oestrogen receptor-positive
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Breastcancer/Fulvestrant-Ribociclib.pdf

Acalabrutinib

Description: Chemotherapy Protocol Chronic Lymphocytic Leukaemia Regimen Acalabrutinib • CLL – Acalabrutinib Indication • First-line t
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/CLL/Acalabrutinib.pdf

Registering New Studies into the CRF

Description: SCBR University Hospitals Southampton NHS Foundation Trust Standard Operating Procedure for Accepting Registering New Projects Studies
Url: /Media/Southampton-Clinical-Research/CRF-templates/Registering-New-Studies-into-the-CRF.docx

Chimeric antigen receptor T-cell (CAR-T) therapy discharge medicines - patient information

Description: This factsheet explains what chimeric antigen receptor T-cell (CAR-T) therapy is and what it involves so you know what
Url: /Media/UHS-website-2019/Patientinformation/Cancercare/Chimeric-antigen-receptor-T-cell-CAR-T-therapy-discharge-meds-3635-PIL.pdf

Annual-report-and-quality-account-2019-20

Description: ANNUAL REPORT AND ACCOUNTS 2019/20 Incorporating the quality account 2019/20 Page 2 University Hospital Southampton NHS Foundation Trust Annual
Url: /Media/UHS-website-2019/Docs/About-the-Trust/Annual-reports-and-quality-accounts/annual-report-and-quality-account-2019-202.pdf

Ipilimumab(1mg/kg)-Nivolumab(3mg/kg)

Description: Chemotherapy Protocol RENAL CANCER IPILIMUMAB (1mg/kg)-NIVOLUMAB(3mg/kg) Regimen • Renal – Ipilimumab (1mg/kg)-Nivolumab (3mg/kg) Indication • Ipilimumab in
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Renal-cell/Ipilimumab1mgkg-Nivolumab3mgkg.pdf

MyelomaRCDCyclophosphamideDexamethasoneLenalidomidel(RCD)Ver1

Description: Chemotherapy Protocol MULTIPLE MYELOMA RCD-CYCLOPHOSPHAMIDE-DEXAMETHASONE-LENALIDOMIDE There are multiple versions of this protocol in use. Pleas
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Myeloma/MyelomaRCDCyclophosphamideDexamethasoneLenalidomidelRCDVer1.pdf

MDT Leaflet_Young Lives vs Cancer Eligibility Criteria 2021

Description: YOUNG LIVES VS CANCER ELIGIBILITY FOR HEALTH PROFESSIONALS YOUNG LIVES VS CANCER: WHO WE ARE Cancer is shocking, overwhelming, isolating... and
Url: /Media/UHS-website-2019/Docs/Services/Cancer-care/mdt-leaflet-young-lives-vs-cancer-eligibility-criteria-2021.pdf

Docetaxel-Pertuzumab/TrastuzumabSC

Description: Chemotherapy Protocol BREAST CANCER Docetaxel-Pertuzumab/Trastuzumab SC Regimen • Breast Cancer – Docetax
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Breastcancer/Docetaxel-PertuzumabTrastuzumabSC.pdf

Chlorambucil_2_Obinutuzumab

Description: Chemotherapy Protocol Chronic Lymphocytic Leukaemia Chlorambucil (2 day)-Obinutuzumab (6 cycles) Regimen • CLL – Chlorambucil (2 d
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/CLL/Chlorambucil-2-Obinutuzumab.pdf

261 to 270 of 496

Previous … 25 26 27 28 29 … Next